This data was presented in part in abstract form at the 30th Annual Conference of the Veterinary Cancer Society, San Diego, CA, USA, October 2010.
Masitinib demonstrates anti-proliferative and pro-apoptotic activity in primary and metastatic feline injection-site sarcoma cells*
Article first published online: 25 AUG 2011
© 2011 Blackwell Publishing Ltd
Veterinary and Comparative Oncology
Volume 10, Issue 2, pages 143–154, June 2012
How to Cite
Lawrence, J., Saba, C., Gogal, R., Lamberth, O., Vandenplas, M. L., Hurley, D. J., Dubreuil, P., Hermine, O., Dobbin, K. and Turek, M. (2012), Masitinib demonstrates anti-proliferative and pro-apoptotic activity in primary and metastatic feline injection-site sarcoma cells. Veterinary and Comparative Oncology, 10: 143–154. doi: 10.1111/j.1476-5829.2011.00291.x
- Issue published online: 26 APR 2012
- Article first published online: 25 AUG 2011
- injection-site sarcoma;
- platelet-derived growth factor receptor;
- tyrosine kinase inhibitor;
- vaccine-associated sarcoma
Dysregulation of platelet-derived growth factor receptor (PDGFR) may play a role in feline injection-site sarcoma (ISS) cell growth and viability. Masitinib, a tyrosine kinase inhibitor approved for treatment of canine mast cell tumours, is highly selective for the PDGFR signalling pathway and may offer a new therapeutic approach for this disease. The in vitro effects of masitinib on growth, apoptosis and PDGFR signalling in two novel ISS cell lines were investigated. PDGFR expression was confirmed by Western blot in cell lines derived from a primary ISS tumour (JB) and a corresponding, histologically confirmed ISS lung metastasis (JBLM). Masitinib inhibited cell growth and PDGFR phosphorylation in both cell lines. Higher drug concentrations were required to inhibit growth than to modulate ligand-induced autophosphorylation of PDGFR. These in vitro data suggest that masitinib displays activity against both primary and metastatic ISS cell line and may aid in the clinical management of ISS.